At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35,032 enrolled
Drug / intervention
5ARI +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Treatment Patterns in Men With Benign Prostatic Hypertrophy (Marketscan Database Study)
In Brief
An observational study evaluating 5ARI and AB for Prostatic Hyperplasia. Completed, enrolled 35,032 participants.
Detailed Summary
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
Primary CompletionJun 2010
First PostedMar 2011
TodayJul 2026
First PostedMar 28, 2011
Enrollment StartApr 1, 2010
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.3 years ago
Interventions
5ARIdrug
Dutasteride or Finasteride
ABdrug
Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin